10-Q: Inspire Medical Q3 Profit Halves Amid New Product Delays, GLP-1 Impact

Inspire Medical Systems reported a 46.3% drop in Q3 net income to $9.9 million despite a 10.5% revenue increase, as new product launch delays and GLP-1 drug impacts weigh on performance.

Summary

• Revenue for the three months ended September 30, 2025, increased by 10.5% to $224.5 million, and by 14.2% to $642.9 million for the nine months ended September 30, 2025, compared to the same periods in 2024.
• Net income for the three months ended September 30, 2025, decreased by 46.3% to $9.9 million, and by 49.0% to $9.3 million for the nine months ended September 30, 2025, compared to the same periods in 2024.
• Gross margin improved to 85.8% for Q3 2025 (from 84.1%) and 84.9% for the nine months (from 84.5%), driven by increased sales volume and a higher sales mix of the less expensive-to-manufacture Inspire V system.
• Operating income for Q3 2025 decreased by 32.6% to $9.6 million, while for the nine months, it increased by 15.3% to $4.8 million.
• Selling, General and Administrative (SG&A) expenses increased significantly by 21.8% in Q3 and 19.2% for the nine months, primarily due to higher marketing costs (advertising) and increased compensation/headcount.
• Research and Development (R&D) expenses decreased by 7.2% in Q3 and 6.6% for the nine months, mainly due to lower ongoing R&D costs for next-gen products, partially offset by increased compensation.
• Cash and cash equivalents decreased by $37.3 million to $112.8 million as of September 30, 2025, from $150.2 million at the beginning of the year, largely due to share repurchases.
• The company repurchased 552,423 shares for $50.0 million under its 2025 share repurchase program during Q3 2025, with $150.0 million remaining available.
• An impairment charge of $4.0 million was recognized on a strategic investment during the nine months ended September 30, 2025.

Sentiment

Score: 4

Explanation: While revenue continues to grow and gross margins improved, the substantial decline in net income, coupled with explicit warnings about revenue impact from product transition delays and the emergence of new competitive/regulatory pressures (GLP-1s, DOJ CID, patent lawsuits), indicates a challenging period for profitability and operational execution.

Positives

• Continued revenue growth: Q3 revenue increased by 10.5% to $224.5 million, and nine-month revenue increased by 14.2% to $642.9 million.
• Gross margin expansion: Q3 gross margin improved to 85.8% from 84.1%, and nine-month gross margin improved to 84.9% from 84.5%, driven by increased sales volume and a higher sales mix of the more cost-effective Inspire V system.
• Improved operating cash flow: Net cash provided by operating activities increased to $64.5 million for the nine months ended September 30, 2025, from $61.1 million in the prior year.
• Positive shift in investing activities: Net cash provided by investing activities was $33.4 million for the nine months, a significant improvement from $116.9 million used in the prior year.
• Dismissal of two significant lawsuits: The City of Hollywood Lawsuit (securities class action) and the Hollin Lawsuit (stockholder derivative) were both dismissed.
• Belief that GLP-1s may ultimately increase the eligible patient pool for Inspire therapy by addressing lateral wall collapse, potentially making more patients candidates for Inspire therapy.

Negatives

• Significant decline in profitability: Net income decreased by 46.3% in Q3 to $9.9 million and by 49.0% for the nine months to $9.3 million.
• Operating income decline: Q3 operating income decreased by 32.6% to $9.6 million.
• Increased SG&A expenses: SG&A expenses rose by 21.8% in Q3 and 19.2% for the nine months, outpacing revenue growth and impacting overall profitability.
• Decrease in cash and investments: Cash, cash equivalents, and available-for-sale debt securities decreased by $105.6 million since December 31, 2024.
• Impairment charge: A $4.0 million impairment charge on a strategic investment was recorded during the nine months ended September 30, 2025.
• Increased income taxes: Income tax expense nearly doubled in Q3 to $3.6 million and increased by 71.2% for the nine months to $6.0 million.

Risks

• Patients and physicians are delaying Inspire therapy until the Inspire V system is available at their location, and customers are using existing Inspire IV inventory, which is expected to impact consolidated revenue through the end of 2025 or early 2026.
• The increasing popularity and FDA approval of GLP-1 drugs (e.g., Zepbound) for OSA could reduce demand for Inspire therapy for certain patient indications, despite the company's belief in an expanded overall eligible patient pool.
• Revenue growth has been and may continue to be adversely impacted by a lack of ENT surgeon capacity.
• The company experiences seasonality in its first and fourth fiscal quarters, with higher sales in Q4 due to met insurance deductibles and lower sales in Q1 due to deductible resets, and now also during summer months due to elective surgery postponements.
• Dependence on third-party suppliers, many of whom are single-source, poses a risk of supply disruptions.
• Subject to the risk of inventory obsolescence, excess, and expiration, especially with new product introductions, leading to potential impairment charges (e.g., $2.1 million charge for Inspire IV components).
• Subject to a civil investigative demand (CID) from the Department of Justice regarding alleged False Claims Act and Anti-Kickback Statute violations related to marketing, promotion, and reimbursement practices.
• Involved in ongoing patent infringement lawsuits, having initiated one against Nyxoah SA and subsequently being sued by Nyxoah for alleged infringement.
• Global macroeconomic conditions, including inflation, higher interest rates, increased capital/shipping costs, tariffs, and weakening foreign currency exchange rates, could cause customers to decrease or delay orders.

Future Outlook

The company expects patients and physicians to continue delaying Inspire therapy until the Inspire V system is fully available at customer locations and existing Inspire IV inventory is used, primarily through the end of 2025 or early 2026. Direct-to-consumer expenditures are anticipated to increase significantly over 2024 levels during the remainder of 2025, with an emphasis on expanding digital advertising and enhancing the digital scheduling program for patient access. R&D expenses are also expected to increase during the remainder of 2025, primarily related to the ongoing development of the SleepSync platform and next-generation products. Further capital expenditures are anticipated in 2025 for manufacturing equipment, the SleepSync platform, computer hardware and software, and leasehold improvements. The company believes its existing cash, cash equivalents, and investments, along with cash flows from operations, will provide sufficient liquidity for at least the next 12 months, but may seek additional sources of liquidity and capital through equity or debt financings beyond that period.

Management Comments

• "We expect to continue to see patients delay Inspire therapy until centers meet these criteria and Inspire V is available at their location through the end of 2025 or early 2026."
• "We anticipate that the occurrence of patients and physicians delaying Inspire therapy and the destocking by some of our customers of their existing Inspire IV inventory may impact our consolidated revenue until Inspire V is fully available at our customer locations and our customers have used their existing Inspire IV inventory, which we expect to primarily occur in the remainder of 2025 and early 2026."
• "We believe that some of these patients [using GLP-1s] will see a reduction in their BMI into our indication, and that some of those patients will not have their OSA fully resolved and will require further treatment. This reinforces our belief that the overall number of patients eligible for Inspire therapy will increase due to the availability of GLP-1s, although there can be no assurance of such benefit at this time."
• "We believe our balance sheet and liquidity as of November 3, 2025 provides us with flexibility, and that our cash, cash equivalents, and investments will satisfy our operating needs and capital expenditures for at least the next 12 months."

Industry Context

The medical technology industry for obstructive sleep apnea (OSA) treatment is experiencing a dynamic shift with the increasing popularity and FDA approval of glucagon-like peptide 1 (GLP-1) drugs, such as Zepbound, for obesity and OSA. While these drugs present a potential competitive alternative to surgical interventions like Inspire therapy, Inspire Medical Systems posits that they may also expand the overall patient pool eligible for its device. This is based on the understanding that GLP-1s primarily address lateral wall collapse, potentially making patients with residual tongue base collapse (Inspire's specific indication) more suitable candidates for the neurostimulation therapy. A recent survey of sleep physicians by Inspire suggests an increase in patients seeking OSA diagnosis and treatment due to GLP-1 availability, indicating a potential for complementary or sequential treatment pathways in the evolving market.

Management Changes

Corporate Governance

Legal Proceedings

• The company received a civil investigative demand (CID) from the Department of Justice U.S. Attorneys Office for the District of Minnesota on January 17, 2025, pursuant to the False Claims Act, concerning allegations of false claims, including those arising from violations of the Anti-Kickback Statute, submitted to government payors in connection with its implant. The company is cooperating with the investigation.
• Inspire initiated a legal action against Nyxoah SA and its subsidiary Nyxoah, Inc. on May 30, 2025, in the United States District Court for the District of Delaware, alleging patent infringement by Nyxoah's Genio product.
• Nyxoah filed a lawsuit against Inspire on September 15, 2025, in the United States District Court for the District of Delaware, alleging that the Inspire IV and Inspire V devices infringe certain of Nyxoah's patents.
• The purported federal securities law class action, City of Hollywood Firefighters Pension Fund v. Inspire Medical Systems, Inc., et. al., was dismissed with prejudice on March 24, 2025.
• The stockholder derivative lawsuit, Lawrence Hollin v. Herbert, et al., was voluntarily dismissed on September 5, 2024.

Related Party Transactions

• The company has a Cost Sharing Agreement with an entity controlled by its Chief Executive Officer for a corporate suite at a sports and entertainment venue. Inspire reimbursed the entity $0.1 million for the three months ended September 30, 2025, and $0.3 million for the nine months ended September 30, 2025, for 50% use of the suite.

Stakeholder Impact

• Shareholders: Impacted by declining net income, share repurchase programs (reducing share count but using cash), and ongoing legal/regulatory proceedings (DOJ CID, patent lawsuits). Potential for future share price volatility due to product transition delays and GLP-1 drug competition.
• Patients: Potential for delays in receiving Inspire therapy due to the transition to Inspire V. Potential for new treatment options (GLP-1s) that may or may not lead to Inspire therapy.
• Physicians/Hospitals/ASCs: Facing training, contracting, and onboarding criteria for Inspire V, leading to delays in adoption. Also impacted by patient decisions regarding GLP-1s.
• Employees: Stock-based compensation is a significant component of compensation. Accelerated stock-based compensation expense for retirement-eligible employees.
• Suppliers: The company's dependence on single-source suppliers creates risk for continuity of supply.

Next Steps

• Continue to make Inspire IV systems available in the U.S. as inventory levels allow.
• Seek appropriate regulatory clearances for Inspire V in foreign markets.
• Refine and optimize outreach strategies, with an emphasis on expanding digital advertising efforts to reach more qualified patients.
• Enhance and expand the digital scheduling program for patient access to care during the remainder of 2025.
• Increase direct-to-consumer marketing efforts in existing and new markets.
• Increase the number of U.S., European, and Japanese sales representatives and sales support personnel.
• Continue investments in research and development efforts for future generations of Inspire systems and to support future regulatory submissions for expanded indications and new markets.
• Anticipate further capital expenditures in 2025 for manufacturing equipment, SleepSync platform, computer hardware and software, and leasehold improvements.
• Evaluate the impact of ASU 2023-09 (Improvements to Income Tax Disclosures) on income tax disclosures.
• Evaluate the impact of ASU 2024-03 (Disaggregation of Income Statement Expenses) on financial statement disclosures.
• Evaluate the impact of ASU 2025-06 (Targeted Improvements to the Accounting for Internal-Use Software) on financial statements and disclosures.
• Cooperate with the Department of Justice investigation regarding the civil investigative demand.
• Defend claims vigorously in the patent infringement lawsuit filed by Nyxoah.

Key Dates

Recommendation

While Inspire Medical Systems demonstrates continued revenue growth and improved gross margins, the significant decline in net income and operating income raises concerns about profitability. The ongoing transition to the Inspire V system, coupled with patient and physician delays and inventory destocking, is explicitly noted to impact future revenue. Furthermore, the emergence of GLP-1 drugs as a treatment for OSA introduces a new competitive dynamic, and the company is facing a Department of Justice investigation and new patent infringement lawsuits. These factors create considerable uncertainty and potential headwinds, suggesting a "hold" recommendation until there is clearer visibility on the resolution of these challenges and a return to stronger profitability.

Keywords

Inspire Medical Systems, INSP, Obstructive Sleep Apnea, OSA, Inspire therapy, neurostimulation, medical technology, Q3 2025 earnings, 10-Q, financial results, GLP-1, Zepbound, Inspire V, Inspire IV, patent infringement, share repurchase, SEC filing